These data suggest that targeting on IL-1β, IL-6, NOS3, PON1 or EGFR may be effective in the treatment of AD, which supports our finding that proteins with good molecular docking are the important target proteins for neuroprotection of GpM in the treatment of AD. This evidence concerns the gene NOS3 and Alzheimer disease.